Abbott Molecular (AM) is making the promise of personalized medicine a reality. As a leader in the field of molecular diagnostics, Abbott Molecular has been developing and commercializing successful products for more than 25 years. In 2001, AM's PathVysion was the first gene-based test (HER2 amplification) linked to a therapy [Herceptin®, (trastuzumab)]. Today, Abbott Molecular offers a broad range of technology and expertise to enable collaborative partnerships aimed at transforming patient care. To learn more about companion diagnostics, visit AbbottCDx.com.